Military and Defense Semiconductor Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The global military & defense semiconductor market was valued at USD 25 Billion in 2023 and is predicted to record an 8% CAGR from 2024 to 2032, primarily propelled by the relentless pace of technological advancements and the escalating defense expenditures worldwide. This market's growth is intricately linked to the modernization efforts of armed forces globally, as nations increasingly recognize the critical role played by advanced semiconductor solutions in shaping the capabilities of contemporary military applications.
According to the latest news, in December 2023, the US Army partnered with USC Institute for Creative Technologies to develop a new app for soldiers to teach them how to use AI tools. Game-If-AI, the app, will help personnel deployed in non-technical and technical areas. As defense agencies invest heavily in the integration of AI, ML, and edge computing into their systems, the demand for cutting-edge semiconductor solutions continues to soar, setting the stage for unprecedented growth in the Military & Defense Semiconductor Market.
The military & defense semiconductor market is classified based on mounting technology, application, and region.
The weapons application segment is anticipated to generate massive revenues in the market by 2032 due to the integration of semiconductors in precision-guided munitions. Electronic warfare systems, and smart weapons have become indispensable for modern military capabilities. The relentless pursuit of accuracy, range, and efficiency in weaponry is driving investments in semiconductor technologies that enhance the performance and reliability of defense systems.
The through hole technology mounting segment will grow significantly through 2032 owing to its role in ensuring robust connectivity and durability in harsh operational environments. Through hole technology, with its ability to provide mechanical strength and stability to components, is crucial for applications where reliability is paramount. This segment is experiencing a surge in demand as military and defense systems require semiconductors that can withstand extreme conditions while maintaining optimal performance.
Europe Military & Defense Semiconductor Market is expected to expand significantly by 2032, exhibiting substantial growth and innovation. European nations are actively investing in R&D to enhance their defense capabilities, leading to a surge in demand for advanced semiconductor solutions. The region's commitment to fostering collaboration between government agencies, research institutions, and private sector companies is further propelling the development of cutting-edge semiconductor technologies for defense applications.
- Chapter 1 Methodology
- 1.1 Market segmentation
- 1.2 Market definitions
- 1.3 Research design
- 1.4 Market size estimates and calculations
- 1.4.1 Approach 1: Company shares analysis
- 1.4.2 Approach 2: Demand side modelling approach
- 1.5 Key trends for market estimates
- 1.6 Forecast model
- 1.7 Primary research & validation
- 1.7.1 Primary sources
- 1.7.2 Data mining sources
- 1.7.2.1 Paid sources
- 1.7.2.2 Public sources
- Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis, 2021 - 2032
- 2.2 Disease trends
- 2.3 Therapy type
- 2.4 Route of administration trends
- 2.5 End user trends
- 2.6 Regional trends
- Chapter 3 Metabolic Disorder Therapeutics Market Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of metabolic disorders
- 3.2.1.2 Rising R&D activities for developing novel therapeutics
- 3.2.1.3 Growth in awareness and screening programs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost associated with treatment
- 3.2.2.2 Stringent regulatory requirements
- 3.3 Growth potential analysis
- 3.3.2 By therapy type
- 3.3.3 By route of administration
- 3.3.4 By end user
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Technology landscape
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
- Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.1.1 Novo Nordisk A/S
- 4.1.2 Eli Lilly and Company
- 4.1.3 Sanofi
- 4.2 Company market share analysis, 2023
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
- Chapter 5 Metabolic Disorder Therapeutics Market, By Disease
- 5.1 Diabetes
- 5.2 Hypercholesterolemia
- 5.3 Lysosomal storage diseases
- 5.3.1 Gaucher's disease
- 5.3.2 Metachromatic leukodystrophy
- 5.3.3 Hurler - Scheie
- 5.3.4 Sanfilipo A
- 5.3.5 Other lysosomal storage diseases
- 5.4 Obesity
- 5.5 Inherited metabolic disorders
- Chapter 6 Metabolic Disorder Therapeutics Market, By Therapy Type
- 6.1 Drug therapy
- 6.2 Enzyme replacement therapy
- 6.3 Substrate reduction therapy
- 6.4 Gene therapy
- 6.5 Small molecule-based therapy
- 6.6 Cellular transplantation
- Chapter 7 Metabolic Disorder Therapeutics Market, By Route of Administration
- 7.1 Oral
- 7.2 Parenteral
- 7.3 Other routes of administration
- Chapter 8 Metabolic Disorder Therapeutics Market, By End Use
- 8.1 Hospitals
- 8.2 Specialty clinics
- 8.3 Other end users
- Chapter 9 Metabolic Disorder Therapeutics Market, By Region
- 9.1 North America
- 9.2 Europe
- 9.3 Asia Pacific
- 9.4 Latin America
- 9.5 Middle East and Africa
- Chapter 10 Company Profile
- 10.1 AstraZeneca plc
- 10.1.1 Global overview
- 10.1.2 Business overview
- 10.1.3 Financial data
- 10.1.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.1.4 Product landscape
- 10.1.5 Strategic outlook
- 10.1.6 SWOT analysis
- 10.2 Amgen Inc.
- 10.2.1 Global overview
- 10.2.2 Business overview
- 10.2.3 Financial data
- 10.2.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.2.4 Product landscape
- 10.2.1 SWOT analysis
- 10.3 Boehringer Ingelheim International GmbH
- 10.3.1 Global overview
- 10.3.2 Business overview
- 10.3.3 Financial data
- 10.3.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.3.4 Product landscape
- 10.3.5 SWOT analysis
- 10.4 BioMarin Pharmaceutical, Inc.
- 10.4.1 Global overview
- 10.4.2 Business overview
- 10.4.3 Financial data
- 10.4.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.4.4 Product landscape
- 10.4.5 Strategic outlook
- 10.4.6 SWOT analysis
- 10.5 Biocon Ltd.
- 10.5.1 Global overview
- 10.5.2 Business overview
- 10.5.3 Financial data
- 10.5.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.5.4 Product landscape
- 10.5.5 Strategic outlook
- 10.5.6 SWOT analysis
- 10.6 Bristol-Myers Squibb Company
- 10.6.1 Global overview
- 10.6.2 Business Overview
- 10.6.3 Financial data
- 10.6.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.6.4 Product Landscape
- 10.6.5 SWOT analysis
- 10.7 Cipla
- 10.7.1 Global overview
- 10.7.2 Business Overview
- 10.7.3 Financial data
- 10.7.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.7.4 Product Landscape
- 10.7.5 Strategic outlook
- 10.7.6 SWOT analysis
- 10.8 CHIESI Farmaceutici S.p.A.
- 10.8.1 Global overview
- 10.8.2 Business Overview
- 10.8.3 Financial data
- 10.8.3.1 Annual sales revenue, 2022-2023 (USD Million)
- 10.8.4 Product Landscape
- 10.8.5 Strategic outlook
- 10.8.6 SWOT analysis
- 10.9 Eli Lilly and Company
- 10.9.1 Global overview
- 10.9.2 Business overview
- 10.9.3 Financial data
- 10.9.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
- 10.9.4 Product landscape
- 10.9.5 Strategic outlook
- 10.9.6 SWOT analysis
- 10.10 GlaxoSmithKline plc
- 10.10.1 Global overview
- 10.10.2 Business overview
- 10.10.1 Financial data
- 10.10.1.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.10.2 Product landscape
- 10.10.3 SWOT analysis
- 10.11 Johnson & Johnson
- 10.11.1 Global overview
- 10.11.2 Business overview
- 10.11.3 Financial data
- 10.11.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.11.4 Product landscape
- 10.11.5 SWOT analysis
- 10.12 Merck KGaA
- 10.12.1 Global overview
- 10.12.2 Business Overview
- 10.12.3 Financial data
- 10.12.4 Product Landscape
- 10.12.5 SWOT analysis
- 10.13 Novo Nordisk A/S
- 10.13.1 Global overview
- 10.13.2 Business Overview
- 10.13.3 Financial data
- 10.13.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.13.4 Product landscape
- 10.13.5 Strategic outlook
- 10.13.6 SWOT analysis
- 10.14 Sanofi
- 10.14.1 Global overview
- 10.14.2 Business overview
- 10.14.3 Financial data
- 10.14.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.14.4 Product landscape
- 10.14.5 SWOT analysis
- 10.15 Takeda Pharmaceutical Company Limited
- 10.15.1 Global overview
- 10.15.2 Business overview
- 10.15.3 Financial data
- 10.15.3.1 Annual sales revenue, 2020-2023 (USD Million)
- 10.15.4 Product landscape
- 10.15.5 SWOT analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook